Skip to main content
. Author manuscript; available in PMC: 2012 Dec 27.
Published in final edited form as: JAMA. 2012 Jun 27;307(24):2609–2616. doi: 10.1001/jama.2012.5847

Figure 3.

Figure 3

Event-free survival (EFS) distributions for nodular lymphocyte predominant Hodgkin lymphoma (n=32) versus classical Hodgkin lymphoma (all other histologies, n=56) in children treated with VAMP (vinblastine, doxorubicin, methotrexate, and prednisone) with or without low-dose field radiotherapy. Curves have been truncated at 8 years. The p-value was derived using Cox proportional hazards regression.